REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Regenxbio's ebitda for the twelve months ending Jun 30, 2026 was -$148.78M. For fiscal 2025 it was -$145.58M. The highest annual figure on record is $169.54M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$145.58M | – |
| FY2024 | Dec 31, 2024 | -$217.13M | – |
| FY2023 | Dec 31, 2023 | -$250.81M | – |
| FY2022 | Dec 31, 2022 | -$249.97M | -247.4% |
| FY2021 | Dec 31, 2021 | $169.54M | – |
| FY2020 | Dec 31, 2020 | -$110.83M | – |
| FY2019 | Dec 31, 2019 | -$141.85M | -254.0% |
| FY2018 | Dec 31, 2018 | $92.08M | – |
| FY2017 | Dec 31, 2017 | -$73.20M | – |
| FY2016 | Dec 31, 2016 | -$64.80M | – |
| FY2015 | Dec 31, 2015 | -$23.06M | – |
| FY2014 | Dec 31, 2014 | -$3.68M | – |
| FY2013 | Dec 31, 2013 | -$4.78M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $33.02M | – |
| Q1 FY2026 | Mar 31, 2026 | -$79.51M | -594.4% |
| Q4 FY2025 | Dec 31, 2025 | -$53.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$48.53M | – |
| Q2 FY2025 | Jun 30, 2025 | -$59.37M | – |
| Q1 FY2025 | Mar 31, 2025 | $16.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$47.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$58.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$51.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$59.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$59.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$60.59M | – |
| Q2 FY2023 | Jun 30, 2023 | -$68.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$61.98M | – |
| Q4 FY2022 | Dec 31, 2022 | -$53.65M | -117.0% |
| Q3 FY2022 | Sep 30, 2022 | -$67.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$59.89M | – |
| Q1 FY2022 | Mar 31, 2022 | -$68.94M | – |
| Q4 FY2021 | Dec 31, 2021 | $316.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.52M | -438.1% |
| Q2 FY2021 | Jun 30, 2021 | -$50.03M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$51.55M | – |
| Q3 FY2020 | Sep 30, 2020 | $16.13M | – |
| Q2 FY2020 | Jun 30, 2020 | -$39.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$35.71M | – |
| Q4 FY2019 | Dec 31, 2019 | -$38.40M | -1121.0% |
| Q3 FY2019 | Sep 30, 2019 | -$34.03M | – |
| Q2 FY2019 | Jun 30, 2019 | -$35.12M | -584.7% |
| Q1 FY2019 | Mar 31, 2019 | -$34.29M | -133.3% |
| Q4 FY2018 | Dec 31, 2018 | $3.76M | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.78M | – |
| Q2 FY2018 | Jun 30, 2018 | $7.25M | – |
| Q1 FY2018 | Mar 31, 2018 | $102.86M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.88M | – |
| Q3 FY2017 | Sep 30, 2017 | -$20.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.35M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.37M | – |
| Q4 FY2016 | Dec 31, 2016 | -$20.19M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.51M | – |
See a number that looks wrong?